Aethlon Medical Announces Fiscal Year End March 31, 2026 Financial Results and Corporate Update

Australian oncology study advances into Cohort 3 as enrollment continues Entered the third and final dosing cohort of the Australian oncology study, expanded the Hemopurifier intellectual property portfolio, and maintained a focus on managing operating expenses. Conference Call Today at...